Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Elisa Helen Ignatius, M.D., M.Sc.

Headshot of Elisa Helen Ignatius
Female

Languages: English, French

Expertise

Infectious Disease

Locations

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue
Baltimore, MD 21224 map

The Johns Hopkins Hospital

600 N. Wolfe Street
Baltimore, MD 21287 map

Background

Dr. Elisa H. Ignatius is an infectious diseases and clinical pharmacology specialist at the Johns Hopkins University School of Medicine. She is an expert in the care of patients with nontuberculous mycobacterial (NTM) infections, tuberculosis (TB), bronchiectasis, HIV/AIDS, and other general infectious diseases. Additionally, she provides teaching for medical students, residents, and fellows at the Johns Hopkins University School of Medicine.

Dr. Ignatius earned her M.D. and completed Internal Medicine residency at Emory University School of Medicine. She also obtained a Masters of Science in the Control of Infectious Diseases from the London School of Hygiene and Tropical Medicine, where her research focused on drug-resistant tuberculosis in South Africa. After completing residency, she worked as a co-investigator on HIV prevention clinical trials in Atlanta, Georgia. She then came to Johns Hopkins University where she completed fellowships in both Infectious Diseases and Clinical Pharmacology.

Dr. Ignatius’s research interests focus on treatment optimization strategies for mycobacterial infections (NTM and TB), including regimens of novel and standard drugs.

...read more

Departments / Divisions

Education

Degrees

  • MD; Emory University School of Medicine (2013)

Residencies

  • Internal Medicine; Emory University School of Medicine (2016)

Fellowships

  • Infectious Diseases; Johns Hopkins University School of Medicine (2020)
  • Clinical Pharmacology; Johns Hopkins University School of Medicine (2021)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2019)
  • American Board of Internal Medicine (Internal Medicine) (2016)

Research & Publications

Research Summary

Dr. Ignatius’s research focuses on clinical pharmacology of anti-mycobacterial regimens, for both tuberculosis and nontuberculous mycobacteria infections. This includes clinical trials of drug-drug interactions, pharmacokinetics-pharmacodynamics, and pharmacokinetics-toxicodynamics. By applying clinical trials framework and experience from the study of tuberculosis to the field of nontuberculous mycobacteria, Dr. Ignatius aims to improve the treatment of both diseases with both novel and standard of care regimens.

Selected Publications

View all on PubMed

Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, Denti P. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01196-20. doi: 10.1128/AAC.01196-20. PMID: 33229425; PMCID: PMC7849006

Ignatius EH, Wang K, Karaba A, Robinson M, Avery RK, Blair P, Chida N, Jain T, Petty BG, Siddiqui Z, Melia MT, Auwaerter PG, Xu Y, Garibaldi BT. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. Open Forum Infect Dis. 2021 Jan;8(1):ofaa598. doi: 10.1093/ofid/ofaa598. eCollection 2021 Jan. PubMed PMID: 33537364; PubMed Central PMCID: PMC7798657.

Ignatius EH, Cohen KA, Bishai WR. Getting to the point in point-of-care diagnostics for tuberculosis. J Clin Invest. 2020 Nov 2;130(11):5671-5673. doi: 10.1172/JCI142497. PubMed PMID: 32986020; PubMed Central PMCID: PMC7598045.

Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001. Review. PubMed PMID: 31731986

Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014 Apr 5;383(9924):1230-9. doi: 10.1016/S0140-6736(13)62675-6. Epub 2014 Jan 17. PubMed PMID: 24439237

Activities & Honors

Honors

  • Clinician Scientist Award, Johns Hopkins

Memberships

  • American Society for Clinical Pharmacology & Therapeutics (ASCPT)
  • Infectious Diseases Society of American (IDSA)
  • The International Union Against Tuberculosis and Lung Disease (The Union)
Is this you? Edit Profile
back to top button